Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Parsons

Showing results (831-840 of 865) with videos related to

Pageof 87
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2022
TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family MembersRachel Delahunty, Linh Nguyen, Stuart Craig, et al.
Medrxiv : the Preprint Server for Health Sciences|June 26, 2025
Analysis of <i>BRCA1</i>, <i>BRCA2</i> and <i>PALB2</i> related Fanconi anemia identifies scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
American Journal of Human Genetics|October 31, 2025
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
NPJ Breast Cancer|May 12, 2023
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variantsTaru A Muranen, Anna Morra, Sofia Khan, et al.
British Journal of Cancer|April 19, 2023
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2Denise G O'Mahony, Susan J Ramus, Melissa C Southey, et al.
American Journal of Human Genetics|August 3, 2024
Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing datasetAimee L Davidson, Kyriaki Michailidou, Michael T Parsons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2022
Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic VariantsShuai Li, Valentina Silvestri, Goska Leslie, et al.
Genome Medicine|May 18, 2022
Breast cancer risks associated with missense variants in breast cancer susceptibility genesLeila Dorling, Sara Carvalho, Jamie Allen, et al.
Medrxiv : the Preprint Server for Health Sciences|September 16, 2024
Analysis of more than 400,000 women provides case-control evidence for <i>BRCA1</i> and <i>BRCA2</i> variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Pageof 87

Showing results (831-840 of 865) with videos related to

Sort By:
Pageof 87
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2022
TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family MembersRachel Delahunty, Linh Nguyen, Stuart Craig, et al.
Medrxiv : the Preprint Server for Health Sciences|June 26, 2025
Analysis of <i>BRCA1</i>, <i>BRCA2</i> and <i>PALB2</i> related Fanconi anemia identifies scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variantsHongyan Li, Christoph Engel, Miguel de la Hoya, et al.
American Journal of Human Genetics|October 31, 2025
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotesSharon E Johnatty, Emma Tudini, Michael T Parsons, et al.
NPJ Breast Cancer|May 12, 2023
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variantsTaru A Muranen, Anna Morra, Sofia Khan, et al.
British Journal of Cancer|April 19, 2023
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2Denise G O'Mahony, Susan J Ramus, Melissa C Southey, et al.
American Journal of Human Genetics|August 3, 2024
Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing datasetAimee L Davidson, Kyriaki Michailidou, Michael T Parsons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2022
Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic VariantsShuai Li, Valentina Silvestri, Goska Leslie, et al.
Genome Medicine|May 18, 2022
Breast cancer risks associated with missense variants in breast cancer susceptibility genesLeila Dorling, Sara Carvalho, Jamie Allen, et al.
Medrxiv : the Preprint Server for Health Sciences|September 16, 2024
Analysis of more than 400,000 women provides case-control evidence for <i>BRCA1</i> and <i>BRCA2</i> variant classificationMaria Zanti, Denise G O'Mahony, Michael T Parsons, et al.
Pageof 87